IFNG gene signature overexpression

News alerts, weekly reports and conference planners

IFNG gene signature overexpression	Melanoma	IFNG gene signature overexpression	Melanoma	ipilimumab Sensitive: B - Late Trials ipilimumab Sensitive : B	ipilimumab Sensitive: B - Late Trials ipilimumab Sensitive : B
IFNG gene signature overexpression	Lymphoma	IFNG gene signature overexpression	Lymphoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Head and Neck Cancer	IFNG gene signature overexpression	Head and Neck Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Cervical Cancer	IFNG gene signature overexpression	Cervical Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Urothelial Cancer	IFNG gene signature overexpression	Urothelial Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Melanoma	IFNG gene signature overexpression	Melanoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Pancreatic Cancer	IFNG gene signature overexpression	Pancreatic Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Renal Cell Carcinoma	IFNG gene signature overexpression	Renal Cell Carcinoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Melanoma	IFNG gene signature overexpression	Melanoma	nivolumab + 4SC-202 Sensitive: C3 – Early Trials nivolumab + 4SC-202 Sensitive : C3	nivolumab + 4SC-202 Sensitive: C3 – Early Trials nivolumab + 4SC-202 Sensitive : C3
IFNG gene signature overexpression	Melanoma	IFNG gene signature overexpression	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3

IFNG gene signature overexpression

Associations